Renovorx appoints angela gill nelms as chief operating officer

Los altos, calif.--(business wire)--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary renovorx trans-arterial micro-perfusion (renovotamptm) therapy platform, today announced that angela gill nelms has joined the company as chief operating officer (“coo”). “angela is a growth-oriented operational leader with experience in clinical trial management, a proven track record for driving innovation,
RNXT Ratings Summary
RNXT Quant Ranking